Radiopharmaceutical developer Navidea Biopharmaceuticals has sublicensed its NAV4694 PET imaging agent to Cerveau Technologies.
The nonbinding term sheet authorizes Cerveau to conduct research using the imaging agent, as well as develop and commercialize it in Australia, Canada, China, and Singapore.
Navidea's NAV4694 is a beta-amyloid imaging agent believed to facilitate the diagnosis of early-onset Alzheimer's disease using PET.
